{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:23:13Z","timestamp":1788276193111,"version":"build-2803163510"},"reference-count":18,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lipoatrophy, the localized loss of subcutaneous fat, is a rare complication of insulin therapy that persists despite advancements in insulin formulations and delivery systems. This case report describes a 58-year-old woman with type 1 diabetes mellitus who developed considerable abdominal wall lipoatrophy 4 months after initiating insulin pump therapy. Management included changing the infusion cannula type, rotating insertion sites, and switching insulin analogues, resulting in stabilization and complete improvement of lipoatrophy over 16 months. A diagnostic and management algorithm is proposed, incorporating site rotation, cannula and insulin type modifications, and potential adjunctive therapies including topical sodium cromoglycate and corticosteroids.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf168","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T07:30:47Z","timestamp":1751787047000},"source":"Crossref","is-referenced-by-count":1,"title":["Insulin Pump-Induced Lipoatrophy: Proposed Diagnostic and Management Algorithm"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7323-0099","authenticated-orcid":false,"given":"Harsan","family":"Kanagaretnam","sequence":"first","affiliation":[{"name":"Endocrinology Department, Concord Repatriation General Hospital , Concord, New South Wales 2139 ,","place":["Australia"]},{"name":"The University of Sydney Concord Clinical School , Sydney, New South Wales 2139 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-9880","authenticated-orcid":false,"given":"Kajanan","family":"Parameshwaran","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Concord Repatriation General Hospital , Concord, New South Wales 2139 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0721-5520","authenticated-orcid":false,"given":"Avinash","family":"Suryawanshi","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Concord Repatriation General Hospital , Concord, New South Wales 2139 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"1","key":"2025081304270460400_luaf168-B1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s42000-021-00324-z","article-title":"Lipoatrophy, a rare complication of diabetes: a single-center experience","volume":"20","author":"Xatzipsalti","year":"2021","journal-title":"Hormones (Athens)"},{"issue":"1","key":"2025081304270460400_luaf168-B2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2337\/diacare.24.1.174","article-title":"Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause?","volume":"24","author":"Griffin","year":"2001","journal-title":"Diabetes Care"},{"issue":"3","key":"2025081304270460400_luaf168-B3","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2337\/diacare.26.3.953","article-title":"A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications?","volume":"26","author":"Ampudia-Blasco","year":"2003","journal-title":"Diabetes Care"},{"issue":"9","key":"2025081304270460400_luaf168-B4","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/pdi.1985","article-title":"Progressive and disabling lipoatrophy associated with insulin aspart via a continuous subcutaneous insulin infusion","volume":"32","author":"Boland","year":"2015","journal-title":"Pract Diabetes"},{"issue":"1","key":"2025081304270460400_luaf168-B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-5996-3-33","article-title":"Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report","volume":"3","author":"Chantelau","year":"2011","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"2025081304270460400_luaf168-B6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2337\/dc07-1739","article-title":"Human insulin analog\u2013induced lipoatrophy","volume":"31","author":"Lopez","year":"2008","journal-title":"Diabetes Care"},{"issue":"1","key":"2025081304270460400_luaf168-B7","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1752-1947-8-223","article-title":"Insulin-induced localized lipoatrophy preceded by shingles (herpes zoster): a case report","volume":"8","author":"Chantelau","year":"2014","journal-title":"J Med Case Rep"},{"issue":"7","key":"2025081304270460400_luaf168-B8","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1210\/jc.2009-2773","article-title":"Insulin-induced lipoatrophy and lipoatrophic diabetes: ultrastructural analysis and gene expression profiling of subcutaneous adipose tissue","volume":"95","author":"Milan","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6230","key":"2025081304270460400_luaf168-B9","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1136\/bmj.280.6230.1500","article-title":"Insulin-induced lipoatrophy: an immune pathogenesis","volume":"281","author":"Reeves","year":"1980","journal-title":"BMJ"},{"issue":"1","key":"2025081304270460400_luaf168-B10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/adc.2010.183731","article-title":"Lipoatrophy with insulin analogs in type I diabetes","volume":"96","author":"Babiker","year":"2011","journal-title":"Arch Dis Child"},{"issue":"2","key":"2025081304270460400_luaf168-B11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2337\/diacare.27.2.625","article-title":"A case of lipoatrophy with lispro insulin without insulin pump therapy","volume":"27","author":"Arranz","year":"2004","journal-title":"Diabetes Care"},{"issue":"12","key":"2025081304270460400_luaf168-B12","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.2337\/dc13-1123","article-title":"Cromolyn sodium for insulin-induced lipoatrophy: old drug, new use","volume":"36","author":"Phua","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"2025081304270460400_luaf168-B13","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/diacare.29.04.06.dc06-0004","article-title":"Human insulin\u2013induced lipoatrophy: a successful treatment with glucocorticoid","volume":"29","author":"Ramos","year":"2006","journal-title":"Diabetes Care"},{"issue":"4","key":"2025081304270460400_luaf168-B14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2337\/diab.26.4.296","article-title":"Use of dexamethasone in treatment of insulin lipoatrophy","volume":"26","author":"Kumar","year":"1977","journal-title":"Diabetes"},{"issue":"2","key":"2025081304270460400_luaf168-B15","first-page":"151","article-title":"Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus","volume":"6","author":"Mu","year":"2000","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"2025081304270460400_luaf168-B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00128071-200708010-00003","article-title":"Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs","volume":"8","author":"Radermecker","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"2025081304270460400_luaf168-B17","first-page":"167","article-title":"New and emerging agents in the management of lipodystrophy in HIV-infected patients","volume":"2","author":"Bonnet","year":"2010","journal-title":"HIV AIDS (Auckl)"},{"key":"2025081304270460400_luaf168-B18","first-page":"29","article-title":"Association of different insulin delivery systems with glycemic variability and patient-reported outcomes: a systematic review and meta-analysis","volume":"16","author":"Chao","year":"2023","journal-title":"Diabetes Metab Syndr Obes"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf168\/63898704\/luaf168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/9\/luaf168\/63898704\/luaf168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T08:27:11Z","timestamp":1755073631000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf168\/8219798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,17]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,7,17]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf168","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,7,17]]},"article-number":"luaf168"}}